2025-11-25, 2:17:04 p.m.
BOSTON, MA — November 26, 2025 — Leads & Copy — Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView have announced a collaborative effort to improve breast cancer risk assessment by identifying more women at high risk.
The collaboration aims to address a critical gap in breast cancer risk assessment without increasing administrative burdens, bringing together leaders in breast cancer care. The agreement leverages the strengths of each company:
Clairity, developer of Clairity Breast, is the first FDA-authorized tool for estimating a woman’s five-year breast cancer risk using routine mammograms. Myriad Genetics offers the MyRisk® Hereditary Cancer Test with RiskScore®, which incorporates genetics, clinical factors (Tyrer-Cuzick), and polygenic risk. MagView provides comprehensive software solutions for breast imaging centers.
Clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk platform, which supports breast cancer risk assessment programs across the United States.
Jeff Luber, CEO of Clairity, stated that the integration with MagView alongside Myriad gives clinicians a more actionable view of risk compared to using age and family history alone. Clairity Breast uses AI-powered risk assessment to identify women at the highest risk from a routine mammogram.
Sam Raha, President and CEO of Myriad Genetics, noted that effective screening of individuals with elevated cancer risk is crucial. By combining the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, the goal is to empower clinicians with actionable results, enabling earlier and more personalized interventions.
Bryan Chapin, President and CEO of MagView, explained that their platform streamlines the capture, interpretation, and action on risk information. Integrating Clairity and MyRisk into one platform provides providers with a unified tool for proactive breast health management and improves workflow efficiency.
Matt Scalo can be reached at (801) 584-3532 or IR@myriad.com for investor inquiries.
Kate Schraml can be reached at (224) 875-4493 or PR@myriad.com for media inquiries.
Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram.
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties.
MagView’s Luminary Risk software embeds into EHRs to enable breast centers to adopt a more personalized approach to breast cancer screening, focusing on patient experience and staff efficiency. MagView is utilized by more than 2,500 facilities across the U.S., including many of the nation’s top cancer centers.
Source: Myriad Genetics, Inc.
